# KHINDIVI® (hydrocortisone) PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/hydrocortisone

> The PDUFA target action date for KHINDIVI® (hydrocortisone), sponsored by Eton Pharmaceuticals, Inc. (ETON), is May 28, 2027. Status: scheduled.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, half-year only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### When is the KHINDIVI® (hydrocortisone) PDUFA date?

The PDUFA target action date for KHINDIVI® (hydrocortisone), sponsored by Eton Pharmaceuticals, Inc. (ETON), is May 28, 2027. Status: scheduled. Press release filed with the SEC (EX-99): "KHINDIVI label expansion Prior Approval Supplement (PAS) accepted for review and assigned May 28, 2027 PDUFA date." Last confirmed November 5, 2026. [Calendar and source filings](https://sec-api.dev/pdufa/hydrocortisone)

Source: Press release filed with the SEC (EX-99), accession 0001710340-26-000006, https://www.sec.gov/Archives/edgar/data/1710340/000171034026000006/eton-2026q332026xexx991.htm (retrieved 2026-11-12). Last confirmed 2026-11-05. Cite: https://sec-api.dev/pdufa/hydrocortisone#answer

## Key facts

| Field | Value |
| --- | --- |
| Drug | KHINDIVI® (hydrocortisone) |
| Codes |  |
| Sponsor | Eton Pharmaceuticals, Inc. (ETON) https://sec-api.dev/companies/eton/catalysts |
| Indications |  |
| Modality |  |
| FDA designations | none disclosed |

## Timeline

### September 29, 2020: FDA approval

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "NDA213876 ORIG-1 (Type 3 - New Dosage Form): submission_status AP, submission_status_date 20200929, review_priority STANDARD; sponsor_name ETON; product ALKINDI SPRINKLE (HYDROCORTISONE)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA213876%22

### May 28, 2025: FDA approval

- Status: completed, approved. Date confidence: exact.
- First seen 2025-05-28, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "NDA218980 ORIG-1 (Type 3 - New Dosage Form): submission_status AP, submission_status_date 20250528, review_priority STANDARD; sponsor_name ETON; product KHINDIVI (HYDROCORTISONE)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA218980%22
- Press release filed with the SEC (EX-99) (accession 0001437749-25-018698): "DEER PARK, Ill., MAY 28, 2025 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc ("Eton" or "the Company") (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced the U.S. Food and Drug Administration (FDA) approval of a New Drug Application (NDA) for KHINDIVI™ (hydrocortisone) Oral Solution as a replacement therapy in pediatric patients five years of age and older with adrenocortical insufficiency." https://www.sec.gov/Archives/edgar/data/1710340/000143774925018698/ex_822865.htm

### 1H 2026: NDA/BLA submission

- Status: scheduled. Date confidence: half.
- First seen 2025-08-07, last confirmed 2025-08-07.
- Press release filed with the SEC (EX-99) (accession 0001437749-25-025438): "A pre-submission meeting with the FDA is scheduled for September, and the Company expects to file a supplement to the existing KHINDIVI New Drug Application (NDA) in the first half of 2026, which could allow for approval before the end of 2026." https://www.sec.gov/Archives/edgar/data/1710340/000143774925025438/ex_847128.htm

### May 28, 2027: PDUFA date

- Status: scheduled. Date confidence: exact.
- First seen 2026-11-05, last confirmed 2026-11-05.
- Press release filed with the SEC (EX-99) (accession 0001710340-26-000006): "KHINDIVI label expansion Prior Approval Supplement (PAS) accepted for review and assigned May 28, 2027 PDUFA date." https://www.sec.gov/Archives/edgar/data/1710340/000171034026000006/eton-2026q332026xexx991.htm

Calendar months: [May 2027](https://sec-api.dev/fda-calendar/2027-05)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/hydrocortisone.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "KHINDIVI® (hydrocortisone) PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/hydrocortisone

```bibtex
@misc{secapidev_pdufa_hydrocortisone_20261116,
  title        = {KHINDIVI® (hydrocortisone) PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/hydrocortisone}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_hydrocortisone_20261116","title":"KHINDIVI® (hydrocortisone) PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/hydrocortisone","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
